

CITATION REPORT

List of articles citing

Sildenafil in pediatric pulmonary arterial hypertension

DOI: 10.4103/0022-3859.159421

Journal of Postgraduate Medicine, 2015, 61, 181-92.

Source: <https://exaly.com/paper-pdf/89627524/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). <i>Journal of Controlled Release</i> , 2017 , 250, 96-106	11.7	23
22	Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation. <i>Pediatric Cardiology</i> , 2017 , 38, 1703-1708	2.1	2
21	Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Clinical Drug Investigation</i> , 2019 , 39, 1093-1107	3.2	8
20	Safety of enteral sildenafil in hemodynamically unstable children. <i>Cardiology in the Young</i> , 2019 , 29, 589-593	0	0
19	Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. <i>ASN Neuro</i> , 2019 , 11, 1759091419832444	5.3	5
18	In the child with pulmonary hypertension, does treatment with enteral sildenafil compared with a slow wean from nitric oxide alone prevent rebound pulmonary hypertension and allow for discontinuation of nitric oxide?. <i>Archives of Disease in Childhood</i> , 2020 , 105, 410-412	2.2	2
17	Orphan Formulations for Pediatric Use: Development and Stability Control of Two Sildenafil Citrate Solutions for the Treatment of Pulmonary Hypertension. <i>AAPS PharmSciTech</i> , 2020 , 21, 221	3.9	0
16	Benefits of perioperative sildenafil therapy in children with a ventricular septal defect with pulmonary artery hypertension on early surgical outcomes. <i>Journal of Cardiac Surgery</i> , 2020 , 35, 3302-3309	1.3	3
15	A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. <i>Journal of Pediatrics: X</i> , 2020 , 5, 100055	0.9	0
14	Should sildenafil be started 2 weeks before the operation in ventricular septal defect patients with high pulmonary vascular resistance?. <i>Journal of Cardiac Surgery</i> , 2021 , 36, 422-423	1.3	0
13	Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines. <i>Global Heart</i> , 2021 , 16, 23	2.9	1
12	The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 668902	5.6	2
11	Role of Sildenafil in Management of Pediatric Acute Respiratory Distress Syndrome. <i>Journal of Pediatric Intensive Care</i> ,	1	0
10	Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. <i>Comprehensive Physiology</i> , 2021 , 11, 2135-2190	7.7	2
9	Treatment of pulmonary arterial hypertension in children. <i>Cardiovascular Diagnosis and Therapy</i> , 2021 , 11, 1144-1159	2.6	1
8	Preparation and characterization of electrospun fibrous scaffolds of either PVA or PVP for fast release of sildenafil citrate. <i>E-Polymers</i> , 2020 , 20, 746-758	2.7	7
7	Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension.. <i>Scientific Reports</i> , 2022 , 12, 7393	4.9	1

- 6 The role of inflammation in cadmium nephrotoxicity: NF- κ B comes into view. **2022**, 308, 120971
- 5 Sildenafil improves pulmonary vascular remodeling in a rat model of persistent pulmonary hypertension of the newborn. **2022**, Publish Ahead of Print,
- 4 Patient-specific and gene-corrected induced pluripotent stem cell-derived endothelial cells elucidate single-cell phenotype of pulmonary veno-occlusive disease. **2022**,
- 3 Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis. 9,
- 2 Pediatric Population Pharmacokinetic Modeling and Exposure-response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison with Adult Data.
- 1 A review search of sildenafil uses in human and in the veterinary medicine. **2023**,